New Delhi, June 24
Newborn screening programme for sickle cell disease (SCD), undertaken between 2019-2024, reduced mortality risk to below 5 per cent from the earlier 20 to 30 per cent, said Dr. Manisha Madkaikar, Director of ICMR- Centre for Research Management and Control of Haemoglobinopathies (CRHCM) in Nagpur.
Madkaikar explained how the Newborn Screening Programme 2019-2024 found that an early diagnosis can significantly boost the outcomes of the chronic, single-gene disorder.
SCD is a chronic, single-gene disorder that causes a debilitating systemic syndrome characterised by chronic anaemia, acute painful episodes, organ infarction, and chronic organ damage, significantly reducing life expectancy.
The genetic blood disorder affects the entire life of the patient, as it leads to various severe health complications.
“Newborn screening programme is recommended for sickle cell disease because as early you diagnose the sickle cell disease, you can initiate comprehensive care in the form of penicillin prophylaxis, some vitamins, appropriate vaccination, and then hydroxyurea therapy,” Madkaikar told.